Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 24,050
Change Today 0.00 / 0.00%
Volume 0.0
TEVA On Other Exchanges
Symbol
Exchange
New York
OTC US
Mexico
Tel Aviv
Frankfurt
As of 10:24 AM 05/21/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

5 Basel Street

P.O. Box 3190

Petach Tikva, 49131

Israel

Phone: 972 3 926 7267

Fax: 972 3 923 4050

Teva Pharmaceutical Industries Limited, together with its subsidiaries and associated companies, engages in the development, manufacture, marketing and distribution of generic, specialty, and other pharmaceutical products. Segments The company operates its business in two segments, Generic medicines and Specialty medicines. In addition to these two segments, the company has other activities, primarily PGT Healthcare, its over-the-counter (OTC) joint venture with The Procter & Gamble Company (P&G). Segments Generic Medicines This segment include chemical and therapeutic equivalents of originator medicines in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. The company is also a manufacturer of Active Pharmaceutical Ingredients (APIs). The company develops, manufactures and sells generic medicines in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. The company offers a range of basic chemical entities, as well as specialized product families, such as sterile products, hormones, narcotics, high-potency drugs and cytotoxic substances, in both parenteral and solid dosage forms. The company produces approximately 300 APIs for its own use and for sale to third parties in various therapeutic areas. The United States: The company is the generic drug company in the United States. The company markets approximately 375 generic products in approximately 1,100 dosage strengths and packaging sizes, including oral, injectables and inhaled products. Europe: The company operates as the generic pharmaceutical company in Europe. Specialty Medicines The Specialty Medicines segment includes other therapeutic areas, such as oncology, women’s health and selected other areas. The Specialty Medicines business, which is focused on delivering solutions to patients and providers via medicines, devices and services in main regions and markets worldwide, includes its core therapeutic areas of central nervous system (CNS) and respiratory medicines (with a focus on asthma and chronic obstructive pulmonary disease). The company also has specialty products in oncology, women’s health and selected other areas. The company’s specialty business also includes its New Therapeutic Entity (NTE) activity, which focuses on enhancing known molecules through new delivery methods, unique combinations or device innovations to address specific patient needs. The company’s specialty medicines organization focuses on its main therapeutic areas and selected local opportunities, with medical and sales and marketing professionals within each area who seek to address the needs of patients and healthcare professionals. A description of the company’s main therapeutic areas and products are as follows: Central Nervous System The company’s CNS portfolio, one of its two core therapeutic areas, includes Copaxone for the treatment of multiple sclerosis, Azilect for the treatment of the symptoms of Parkinson’s disease and Nuvigil for the treatment of sleep disorders, as well as several novel therapies for the treatment of pain care. Copaxone (glatiramer acetate injection 20 mg/mL and 40 mg/mL), is the multiple sclerosis therapy in the United States and worldwide. Copaxone is indicated for the reduction of the frequency of relapses in relapsing-remitting multiple sclerosis (RRMS). The company’s MS portfolio consists of Copaxone, as well as laquinimod, a Phase 3 investigational compound, which is under development. Copaxone, the first non-interferon immunomodulator approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) has a unique mechanism of action that works with the immune system, unlike many therapies that rely on general immune suppression or cell sequestration to exert their effect. In 2014, the company launched Copaxone 40 mg/mL, a higher dose of Copaxone with a three times a week dosing regimen for patients with RRMS, in the United States following approval by the U.S. Food and Drug Administration (FDA). Azilect (rasagiline tablets) is indicated as initial monotherapy and as an adjun

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TEVA:IT 24,050.00 0.00

TEVA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $49.03 USD -0.31
AbbVie Inc $65.48 USD -0.17
Baxter International Inc $67.37 USD -0.17
Eli Lilly & Co $74.30 USD +0.03
Medtronic PLC $77.82 USD -0.59
View Industry Companies
 

Industry Analysis

TEVA

Industry Average

Valuation TEVA Industry Range
Price/Earnings 19.0x
Price/Sales 2.6x
Price/Book 2.3x
Price/Cash Flow 21.2x
TEV/Sales 2.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TEVA PHARMACEUTICAL IND LTD, please visit www.tevapharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.